Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844739 | 0.91 | CA2 (0.55) | NR1H4EPHX2CA1CA2 | |
| SCHEMBL6844731 | 0.91 | NR1H4 (0.48) | RORCNR1H4EPHX2CA1CA2 | |
| SCHEMBL6209714 | 0.90 | ALDH1A1 (0.53) | RORCNR1H4EPHX2ALDH1A1CA1 | |
| SCHEMBL6843413 | 0.88 | NR1H4 (0.52) | NR1H4EPHX2ALDH1A1 | |
| SCHEMBL6842635 | 0.88 | NR1H4 (0.59) | NR1H4EPHX2ALDH1A1GAA | |
| SCHEMBL6211045 | 0.87 | ALDH1A1 (0.50) | NR1H4ALDH1A1PPARGNAMPT | |
| SCHEMBL6842454 | 0.86 | RORC (0.51) | RORCNR1H4EPHX2ALDH1A1GAA | |
| SCHEMBL6845318 | 0.86 | NR1H4 (0.51) | NR1H4EPHX2PPARG | |
| SCHEMBL6843325 | 0.86 | NR1H4 (0.51) | NR1H4EPHX2PPARG | |
| SCHEMBL6843206 | 0.86 | NR1H4 (0.51) | NR1H4EPHX2ALDH1A1PPARGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | RORC 626/4885NR1H4 1615/4885EPHX2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.